| scholarly article | Q13442814 |
| P50 | author | Steven T Poole | Q79780233 |
| P2093 | author name string | Yang Liu | |
| Stephen J Savarino | |||
| Patricia Guerry | |||
| Frédéric Poly | |||
| Milton Maciel | |||
| Cheryl P Ewing | |||
| Mario A Monteiro | |||
| Nelum Dorabawila | |||
| Annette L McVeigh | |||
| Alexander C Maue | |||
| Michael G Prouty | |||
| Renee M Laird | |||
| Brittany Pequegnat | |||
| Eman Omari | |||
| Zuchao Ma | |||
| Christina L Gariepy | |||
| Nina M Schumack | |||
| Kavyashree Satish | |||
| P2860 | cites work | Update on the burden of Campylobacter in developing countries | Q26861272 |
| Structure of CFA/I fimbriae from enterotoxigenic Escherichia coli | Q27655868 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1 | Q28343287 | ||
| Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni | Q33396432 | ||
| Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro | Q33650535 | ||
| Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers | Q34194587 | ||
| Shigella isolates from the global enteric multicenter study inform vaccine development | Q34202171 | ||
| Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study | Q34345075 | ||
| Status of vaccine research and development for Shigella | Q34518265 | ||
| Characterization of Waterborne Outbreak–associatedCampylobacter jejuni, Walkerton, Ontario | Q34548958 | ||
| The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 yea | Q35322779 | ||
| Crystallization and preliminary X-ray diffraction analysis of CfaE, the adhesive subunit of the CFA/I fimbriae from human enterotoxigenic Escherichia coli | Q36294302 | ||
| N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines | Q36445780 | ||
| Genetic analysis of lipooligosaccharide core biosynthesis in Campylobacter jejuni 81-176. | Q36483167 | ||
| A conserved residue in the tip proteins of CS1 and CFA/I pili of enterotoxigenic Escherichia coli that is essential for adherence. | Q36558800 | ||
| Live-attenuated Shigella vaccines | Q36689023 | ||
| Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein | Q36746962 | ||
| Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road | Q36844719 | ||
| Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi | Q37007042 | ||
| Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cells | Q37106403 | ||
| Crystallization and preliminary X-ray diffraction analyses of several forms of the CfaB major subunit of enterotoxigenic Escherichia coli CFA/I fimbriae | Q37115488 | ||
| Characterization and studies of the cellular interaction of native colonization factor CS6 purified from a clinical isolate of enterotoxigenic Escherichia coli | Q37191241 | ||
| Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study. | Q37477196 | ||
| A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression | Q37896946 | ||
| Biological roles of the O-methyl phosphoramidate capsule modification in Campylobacter jejuni | Q39546966 | ||
| Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients | Q39654221 | ||
| Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4(+) T cells following parenteral immunization | Q40100679 | ||
| Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. | Q40123700 | ||
| Spontaneous insertion of an IS1-like element into the virF gene is responsible for avirulence in opaque colonial variants of Shigella flexneri 2a. | Q40148576 | ||
| Genetic control and properties of coli surface antigens of colonization factor antigen IV (PCF8775) of enterotoxigenic Escherichia coli | Q40158481 | ||
| Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. | Q40173337 | ||
| Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial. | Q40199741 | ||
| Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens. | Q40231434 | ||
| Association between Campylobacter infection and Guillain-Barré syndrome | Q41660351 | ||
| The polysaccharide capsule of Campylobacter jejuni modulates the host immune response | Q41993807 | ||
| Characterization of two Campylobacter jejuni strains for use in volunteer experimental-infection studies | Q42058809 | ||
| In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation | Q42120657 | ||
| Persistent abdominal symptoms in US adults after short-term stay in Mexico | Q42224457 | ||
| A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection | Q43461979 | ||
| TEMPO-mediated glycoconjugation: a scheme for the controlled synthesis of polysaccharide conjugates. | Q43512881 | ||
| Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection | Q45237263 | ||
| Rapid and sensitive anthrone-sulfuric acid assay in microplate format to quantify carbohydrate in biopharmaceutical products: method development and validation | Q46879606 | ||
| Enteric Infections in Young Children are Associated with Environmental Enteropathy and Impaired Growth | Q50091455 | ||
| Phase-Variable Changes in the Position of O-Methyl Phosphoramidate Modifications on the Polysaccharide Capsule of Campylobacter jejuni Modulate Serum Resistance. | Q51025260 | ||
| The Campylobacter jejuni NCTC11168 capsule prevents excessive cytokine production by dendritic cells. | Q53224069 | ||
| A point-source outbreak of campylobacteriosis associated with consumption of raw milk. | Q53978894 | ||
| Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay. | Q55333715 | ||
| Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study | Q61622800 | ||
| Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population | Q68134308 | ||
| A phase-variable capsule is involved in virulence of Campylobacter jejuni 81-176 | Q73895625 | ||
| Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli | Q74302631 | ||
| Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | Q81445405 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Escherichia coli | Q25419 |
| Campylobacter | Q131488 | ||
| enterotoxigenic Escherichia coli | Q265214 | ||
| Campylobacter jejuni | Q265488 | ||
| P304 | page(s) | 6695-6702 | |
| P577 | publication date | 2018-09-27 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella | |
| P478 | volume | 36 |
| Q92487093 | Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human |
| Q61446022 | Climate, human behaviour or environment: individual-based modelling of Campylobacter seasonality and strategies to reduce disease burden |
| Q64076203 | Enhanced Immunogenicity and Protective Efficacy of a Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21 |
| Q92106089 | Enterotoxigenic Escherichia coli Infections |
| Q64981615 | Evaluation of a Recombinant Flavobacterium columnare DnaK Protein Vaccine as a Means of Protection Against Columnaris Disease in Channel Catfish (Ictalurus punctatus). |
Search more.